We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.02B
AUM Growth
+$67.6M
Cap. Flow
+$92.8M
Cap. Flow %
9.11%
Top 10 Hldgs %
47.33%
Holding
173
New
45
Increased
25
Reduced
30
Closed
56

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$31.8M
2
FOLD
Amicus Therapeutics
FOLD
+$26.7M
3
ZBH icon
Zimmer Biomet
ZBH
+$24.4M
4
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$22.7M
5
INSM icon
Insmed
INSM
+$21.6M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$17.8M
2
TSRO
TESARO, Inc.
TSRO
+$15.8M
3
EXAS
Exact Sciences
EXAS
+$12.7M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 82.29%
2 Miscellaneous 14.83%
3 Consumer Staples 1.81%
4 Financials 1.05%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
51
DELISTED
Chimerix, Inc.
CMRX
$3.24M 0.32%
148,000
+8,000
+6% +$159K
AEGR
52
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.21M 0.31%
+100,000
New +$3.72M
TSRO
53
PUT
DELISTED
TESARO, Inc.
TSRO
$3.11M 0.31%
+100,000
New +$2.67M
ZLTQ
54
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$3.06M 0.3%
201,628
-384,385
-66% -$6.57M
VRTX icon
55
PUT
Vertex Pharmaceuticals
VRTX
$130B
$2.84M 0.28%
30,000
-270,000
-90% -$18.9M
MGCD
56
DELISTED
MGC Diagnostics Corporation
MGCD
$2.65M 0.26%
316,459
+109,502
+53% +$1.08M
QTNT
57
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.5M 0.25%
+7,500
New +$2.35M
GRCE
58
Grace Therapeutics
GRCE
$46.9M
$2.44M 0.24%
5,347
-631
-11% -$301K
FPRX
59
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.33M 0.23%
150,000
– –
COV
60
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$2.25M 0.22%
25,000
-237,900
-90% -$17.8M
KPTI icon
61
Karyopharm Therapeutics
KPTI
$34.9M
$2.13M 0.21%
+3,043
New +$1.42M
ACHN
62
DELISTED
Achillion Pharmaceuticals
ACHN
$2.12M 0.21%
+280,000
New +$1.12M
GNVC
63
DELISTED
GenVec, Inc.
GNVC
$2.11M 0.21%
82,000
– –
SNN icon
64
Smith & Nephew
SNN
$11.7B
$2.05M 0.2%
+57,408
New +$1.88M
UPI
65
DELISTED
UROPLASTY INC-NEW
UPI
$1.79M 0.18%
668,287
+150,496
+29% +$472K
LGND icon
66
Ligand Pharmaceuticals
LGND
$5.52B
$1.73M 0.17%
+44,632
New +$1.81M
DRRX
67
DELISTED
DURECT Corp
DRRX
$1.65M 0.16%
90,706
– –
ANTH
68
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.62M 0.16%
59,807
– –
OREX
69
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.38M 0.14%
+22,400
New +$1.3M
EXEL icon
70
CALL
Exelixis
EXEL
$14.1B
$1.36M 0.13%
400,000
– –
LUMO
71
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.33M 0.13%
5,556
– –
EPZM
72
DELISTED
Epizyme, Inc
EPZM
$1.33M 0.13%
42,602
-10,000
-19% -$235K
NGNE icon
73
Neurogene
NGNE
$674M
$1.22M 0.12%
6,500
– –
ELOS
74
DELISTED
Syneron Medical Ltd
ELOS
$1.19M 0.12%
115,000
-12,500
-10% -$135K
INCY icon
75
Incyte
INCY
$24.7B
$1.13M 0.11%
20,000
-163,800
-89% -$8.37M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Perceptive Advisors held 173 positions worth $1.02B, up 7.1% from $952M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $92.8M of net new capital in Q2 2014, opening 45 new positions and adding to 25 existing holdings. Its largest new stake was Zimmer Biomet: 249,775 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $17.8M trimmed.

  • Perceptive Advisors's largest Q2 2014 buy was Zimmer Biomet: 249,775 shares worth $25.2M.
  • Perceptive Advisors added most to QUESTCOR PHARMA INC in Q2 2014, an estimated $31.8M increase.
  • Perceptive Advisors's biggest Q2 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $17.8M.
  • Perceptive Advisors fully exited Endocyte, Inc. Common Stock in Q2 2014, selling an estimated $10.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.02B portfolio in Q2 2014.
  • Perceptive Advisors opened 45 new positions and closed 56 in Q2 2014.
  • Perceptive Advisors's portfolio value rose 7.1% quarter-over-quarter to $1.02B.

Based on Perceptive Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.